Skip to main content

Table 1 Model inputs

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Mortality rates Mean Lower bound Upper bound Distribution for PSA Source
 Mortality rate with appropriate empiric treatment 0.018 0.016 0.020 Beta MacVane et al. [23]
 Mortality rate with inappropriate empiric antibiotic 0.072 0.065 0.079 Beta MacVane et al. [23]
Duration of therapy Mean Lower bound Upper bound Distribution for PSA Source
 Duration of empiric therapy 3 days 3 days 3 days Gamma MacVane et al. [23]
 Total LOS for IAAT (inc. empiric therapy) 4 days 3 days 6 days Gamma MacVane et al. [23]
 Additional LOS associated with IIAT 2 days 1 days 2 days Gamma MacVane et al. [23]
Quality of life adjustment Mean Lower bound Upper bound Distribution for PSA Source
 Health utility for survivors 0.85 0.70 1.00 Beta Assumption
Hospital costs Mean Lower bound Upper bound Distribution for PSA Source
 Hospital cost per day (average USD 2015) $1746.27 $1397.01 $2095.52 Gamma AHQR [35]
Discounting Mean Lower bound Upper bound Distribution for PSA Source
 Benefits discount rate (per annum) 3% 3% 3% Gamma AMCP [21]
Drug name Cost per day (USD 2015) Source
 Ceftolozane/tazobactam $249.00 Analy$ource database [1]
 Aztreonam $84.24
 Cefepime $23.04
 Ceftazidime $19.80
 Ceftriaxone $6.40
 Ciprofloxacin $5.26
 Doripenem $125.22
 Imipenem $73.12
 Levofloxacin $6.24
 Meropenem $81.51
 Piperacillin/tazobactam $43.08
 Tigecycline $238.44
 Salvagea $164.31
Lifetime health care expenditure Annual cost Source
 <25 years $477 Basu [20]
 25 to 34 years $790 Basu [20]
 35 to 44 years $947 Basu [20]
 45 to 54 years $1422 Basu [20]
 55 to 64 years $2106 Basu [20]
 65 to 74 years $2758 Basu [20]
 75 years and above $3100 Basu [20]
  1. LOS Length of stay, IAAT Initial appropriate antibiotic therapy, IIAT Initial inappropriate antibiotic therapy
  2. aSalvage therapy consists of meropenem + colistin for cost purposes